Eutilex.Co.Ltd
Eutilex.Co.,Ltd. engages in the discovery and development of immunomodulatory antibody therapeutics to treat cancers and autoimmune diseases. It develops EU101, a fully humanized anti-human 4-1BB monoclonal antibody; EU103, a fully humanized therapeutic monoclonal antibody; and EU501, an 4-1BB mAb-based, tumor antigen targeting bispecific antibodies. The company was founded in 2008 and is headqua… Read more
Eutilex.Co.Ltd (263050) - Total Liabilities
Latest total liabilities as of September 2025: ₩22.09 Billion KRW
Based on the latest financial reports, Eutilex.Co.Ltd (263050) has total liabilities worth ₩22.09 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Eutilex.Co.Ltd - Total Liabilities Trend (2016–2024)
This chart illustrates how Eutilex.Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Eutilex.Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Eutilex.Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
TRF Limited
NSE:TRF
|
India | ₹2.57 Billion |
|
Haesung Optics Co. Ltd
KQ:076610
|
Korea | ₩108.03 Billion |
|
AWC Berhad
KLSE:7579
|
Malaysia | RM191.90 Million |
|
Madras Fertilizers Limited
NSE:MADRASFERT
|
India | ₹20.52 Billion |
|
Rocketboots Ltd
AU:ROC
|
Australia | AU$2.01 Million |
|
SAAM Energy Development Public Company Limited
BK:SAAM
|
Thailand | ฿77.82 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down Eutilex.Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.83 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.43 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Eutilex.Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Eutilex.Co.Ltd (2016–2024)
The table below shows the annual total liabilities of Eutilex.Co.Ltd from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩26.57 Billion | +116.66% |
| 2023-12-31 | ₩12.26 Billion | -26.62% |
| 2022-12-31 | ₩16.71 Billion | -63.11% |
| 2021-12-31 | ₩45.31 Billion | -3.64% |
| 2020-12-31 | ₩47.02 Billion | +256.70% |
| 2019-12-31 | ₩13.18 Billion | +74.17% |
| 2018-12-31 | ₩7.57 Billion | +2.88% |
| 2017-12-31 | ₩7.36 Billion | +29.42% |
| 2016-12-31 | ₩5.68 Billion | -- |